Hutchmed (HCM) said Tuesday the China National Medical Products Administration has granted priority review to the company's new drug application for savolitinib to treat locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients.
The specific indication is for patients with MET amplification who have failed at least two previous systemic treatments, according to the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.